Your browser doesn't support javascript.
loading
Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein.
Davies, Nigel; Hovdal, Daniel; Edmunds, Nicholas; Nordberg, Peter; Dahlén, Anders; Dabkowska, Aleksandra; Arteta, Marianna Yanez; Radulescu, Aurel; Kjellman, Tomas; Höijer, Andreas; Seeliger, Frank; Holmedal, Elin; Andihn, Elisabeth; Bergenhem, Nils; Sandinge, Ann-Sofie; Johansson, Camilla; Hultin, Leif; Johansson, Marie; Lindqvist, Johnny; Björsson, Liselotte; Jing, Yujia; Bartesaghi, Stefano; Lindfors, Lennart; Andersson, Shalini.
Afiliación
  • Davies N; Pharmaceutical Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Hovdal D; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Edmunds N; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge SG8 6HB, UK.
  • Nordberg P; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Dahlén A; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Dabkowska A; Pharmaceutical Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Arteta MY; Pharmaceutical Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Radulescu A; Forschungszentrum Jülich GmbH, Jülich Centre for Neutron Science at Maier-Leibnitz Zentrum, 85748 Garching, Germany.
  • Kjellman T; Pharmaceutical Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Höijer A; Pharmaceutical Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Seeliger F; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Holmedal E; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Andihn E; Global Project and Portfolio Management, AstraZeneca, 43183 Gothenburg, Sweden.
  • Bergenhem N; Alliance Management, BioPharmaceuticals R&D, AstraZeneca, Boston, MA 02451, USA.
  • Sandinge AS; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Johansson C; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Hultin L; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Johansson M; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Lindqvist J; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Björsson L; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Jing Y; Pharmaceutical Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Bartesaghi S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Lindfors L; Pharmaceutical Sciences, R&D, AstraZeneca, 43183 Gothenburg, Sweden.
  • Andersson S; Oligonucleotide Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
Mol Ther Nucleic Acids ; 24: 369-384, 2021 Jun 04.
Article en En | MEDLINE | ID: mdl-33868782
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Nucleic Acids Año: 2021 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Nucleic Acids Año: 2021 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos